MX2012005500A - Agente terapeutico o profilactico para diabetes. - Google Patents

Agente terapeutico o profilactico para diabetes.

Info

Publication number
MX2012005500A
MX2012005500A MX2012005500A MX2012005500A MX2012005500A MX 2012005500 A MX2012005500 A MX 2012005500A MX 2012005500 A MX2012005500 A MX 2012005500A MX 2012005500 A MX2012005500 A MX 2012005500A MX 2012005500 A MX2012005500 A MX 2012005500A
Authority
MX
Mexico
Prior art keywords
therapeutic
prophylactic agent
diabetes
ppar
agonists
Prior art date
Application number
MX2012005500A
Other languages
English (en)
Inventor
Takehiro Takahashi
Hiroki Kumaga
Takashi Kadowaki
Naoto Kubota
Tetsuya Kubota
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2012005500A publication Critical patent/MX2012005500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Un agente terapéutico o profiláctico para diabetes comprendiendo un derivado de tiazolidona como un agonista de PPAR-y como un componente efectivo, el cual agente muestra un efecto secundario reducido del agonista de PPAR-y, se divulga. El agente terapéutico o profiláctico para diabetes comprende un agonista de IP particular tal como beraprost sódico (BPS), y un derivado de tiazolidina tal como pioglitazona o una sal farmacéuticamente aceptable de la misma. Dado que el agente terapéutico o profiláctico de la presente invención muestra una acción hipoglicémica suficientemente efectiva sin acompañarse por efectos secundarios característicos a agonistas de PPAR-y (v. gr., ganancia de peso sorporal), el agente es útil como un agente terapéutico o profiláctico altamente seguro y efectivo para diabetes.
MX2012005500A 2009-11-13 2010-11-12 Agente terapeutico o profilactico para diabetes. MX2012005500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009259544 2009-11-13
PCT/JP2010/070185 WO2011059053A1 (ja) 2009-11-13 2010-11-12 糖尿病の治療または予防薬

Publications (1)

Publication Number Publication Date
MX2012005500A true MX2012005500A (es) 2012-08-03

Family

ID=43991709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005500A MX2012005500A (es) 2009-11-13 2010-11-12 Agente terapeutico o profilactico para diabetes.

Country Status (11)

Country Link
US (1) US9492422B2 (es)
EP (1) EP2500020B1 (es)
JP (1) JP5697260B2 (es)
KR (1) KR101701943B1 (es)
CN (1) CN102655866B (es)
BR (1) BR112012011237A2 (es)
CA (1) CA2780683A1 (es)
ES (1) ES2525748T3 (es)
MX (1) MX2012005500A (es)
TW (1) TWI513462B (es)
WO (1) WO2011059053A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332810B1 (fr) 2012-11-13 2021-01-13 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (es) 1972-03-30 1977-08-01
AR205004A1 (es) 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
JPS5724786B2 (es) 1973-10-31 1982-05-26
GB1583961A (en) 1976-05-11 1981-02-04 Wellcome Found Prostacyclin and derivatives thereof
JPS5495552A (en) 1978-01-06 1979-07-28 Sankyo Co Ltd Prostacyline derivative and its preparation
JPS54130543A (en) 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
JPS55313A (en) 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPS58219162A (ja) 1982-06-14 1983-12-20 Takeda Chem Ind Ltd 置換ビニルカルボン酸誘導体およびその製造法
JPS59137445A (ja) 1983-01-27 1984-08-07 Teijin Ltd プロスタサイクリン類及びその製法
JPS59141536A (ja) 1983-02-01 1984-08-14 Sumitomo Chem Co Ltd 新規ビシクロオクタン誘導体
DE3306123A1 (de) 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3504677A1 (de) 1985-02-12 1986-08-14 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
JPH072640B2 (ja) 1986-06-05 1995-01-18 科研製薬株式会社 抗高脂血症剤
JPS6453672A (en) 1987-08-24 1989-03-01 Nec Corp Audio response type b board of exchange
DE68918726T2 (de) 1988-02-23 1995-03-02 Teijin Ltd Isocarbacyclinderivate enthaltende Antidiabetika.
DE3932403A1 (de) 1989-05-12 1991-04-11 Thomae Gmbh Dr K Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3062230B2 (ja) 1989-12-05 2000-07-10 財団法人相模中央化学研究所 シス―ビシクロ〔４．３．０〕ノナ―２―エン誘導体
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
JP4314742B2 (ja) 1997-09-16 2009-08-19 東レ株式会社 Ｃ−ｃケモカイン産生抑制剤
EP1028113A4 (en) 1998-08-04 2004-10-13 Toray Industries HETEROCYCLIC DERIVATIVES OF BENZENE IN FUSION AND THEIR USE
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
HUP0300990A2 (hu) 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére
ES2636943T3 (es) * 2003-05-09 2017-10-10 Toray Industries, Inc. Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
CA2581337A1 (en) 2004-09-22 2006-03-30 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
JP2006199694A (ja) 2004-12-24 2006-08-03 Ono Pharmaceut Co Ltd Ｇｌｐ−１産生増強剤
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
EP1894567B1 (en) * 2005-06-03 2012-08-15 Mitsubishi Tanabe Pharma Corporation Concomitant pharmaceutical agents and use thereof

Also Published As

Publication number Publication date
TW201127387A (en) 2011-08-16
CA2780683A1 (en) 2011-05-19
KR20120087987A (ko) 2012-08-07
US20120258988A1 (en) 2012-10-11
KR101701943B1 (ko) 2017-02-02
TWI513462B (zh) 2015-12-21
EP2500020A4 (en) 2013-02-06
JPWO2011059053A1 (ja) 2013-04-04
US9492422B2 (en) 2016-11-15
CN102655866A (zh) 2012-09-05
JP5697260B2 (ja) 2015-04-08
WO2011059053A1 (ja) 2011-05-19
BR112012011237A2 (pt) 2019-09-24
CN102655866B (zh) 2013-11-13
EP2500020B1 (en) 2014-09-10
EP2500020A1 (en) 2012-09-19
ES2525748T3 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
SG11201901565VA (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
MY156795A (en) Ip receptor agonist heterocyclic compounds
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
EP2178869A4 (en) INDOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
TN2009000312A1 (en) Fused ring compounds as partial agonists of ppar-gamma
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
BR112015010977A2 (pt) derivado de piridina, sal farmaceuticamente aceitável do mesmo ou solvato do mesmo, pró-droga, composição farmacêutica, inibidor do urat1, agente para o tratamento ou prevenção de uma ou mais doenças, e, composto
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
WO2010087565A3 (ko) 피페린의 신규한 용도
WO2009147170A3 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
UA105229C2 (uk) Фармацевтичний склад
MX371088B (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)fenil]-n-metilacetamida.
MX2012005500A (es) Agente terapeutico o profilactico para diabetes.
MX345169B (es) Agente terapeutico para trastornos de la motilidad.
WO2009126861A3 (en) Triazolopyridine compounds useful as dgat1 inhibitors
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MY162554A (en) Novel benzamide derivatives
MX2013004117A (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
TW200722076A (en) Composition for increasing anti-oxidation activity in blood
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
WO2011096642A3 (ko) 염증성 질환의 예방 및 치료용 약제학적 조성물
MX2009012429A (es) Composicion util para la prevencion de efectos adversos debido al uso de agonistas ppar-gamma.